Sylvia Tobé

---

Sylvia is an experienced biotech industry professional with over ten years of experience in the sector. Prior to joining the T1D fund, she was a Principal on the investment team at Omega Funds, where she focused on early stage investments and company creation across various therapeutic areas including neurology, immunology and rare diseases. She also served as a Board observer for Vanqua Bio, Aerium Therapeutics and Rectify Pharma.

Prior to Omega Funds, Sylvia spent almost 7 years at Ra Pharmaceuticals, a peptide drug discovery company focused on rare diseases associated with complement dysregulation. At Ra, she was involved in the early development of the company’s discovery platform, as well as developing preclinical and translational models for first-in-human studies of its lead product, Zilucoplan, which was recently approved in various countries for generalized myasthenia gravis (gMG). She also provided scientific leadership for multiple discovery programs within the company’s internal pipeline and in collaboration with Merck.

Sylvia earned her Ph.D in Biochemistry Summa Cum Laude from the University Pierre-and-Marie-Curie in Paris, France, while being a full-time visiting fellow in the Department of Genetics at Harvard University where she worked in synthetic biology. She holds an M.S. from Pierre-and-Marie-Curie University in Paris, France and a B.S. in Biochemistry from Joseph-Fourier University in Grenoble, France.